Mechanism of SGLT2 Inhibition in the Kidney

Prior treatment

• Prior and ongoing treatment with SGLT2 inhibitors
• Hematuria of unknown etiology.
  • Prior to entry into the study, any participant with hematuria should be evaluated, the etiology established and documented, and treatment rendered as appropriate.
• Currently receiving a drug regimen that includes steroids, immunosuppressants, or investigational new drugs not associated with this trial.
• Pregnancy.
  • SGLT2 inhibitors are not recommended during the second or third trimester of pregnancy. Moreover, we do not wish to expose pregnant women to conscious sedation that is used during the kidney biopsies.. Women of childbearing potential must have a negative pregnancy test prior to entry and every 2 months during the study and agree to using an effective form of contraception throughout the study, such as the oral contraceptive pill or an intrauterine device. Women who are planning a pregnancy in the next three years will be excluded.

Other illness

• Renovascular or malignant hypertension; uncontrolled hypertension (systolic blood pressure ≥150 or diastolic ≥90 mm Hg)
• Chronic debilitating disorders with or without treatment (e.g., systemic lupus erythematosus \[SLE\], cancer, amyloidosis, and chronic infection) that would interfere with the assessment of kidney function or that might reduce the chances of survival for a sufficient length of time to evaluate the efficacy of treatment.
• Known hypersensitivity to canagliflozin or iodine.
• Allergy to iodine-containing contrast material or shellfish.
• Non-diabetic kidney disease - based on clinical history or kidney biopsy examination.
• History of osteoporotic fracture.
• History of lower-limb amputation irrespective of etiology
• Conditions likely to interfere with informed consent or compliance with the protocol.
• Size of one or both kidneys on ultrasound \< 9 cm (small kidney size is concerning for renal atrophy due to underlying kidney disease) or \> 2 cm discrepancy between left and right kidney sizes based on largest longitudinal diameter
• Hydronephrosis or other important renal ultrasound findings such as significant stone disease
  • Inclusion possible after this has been obtained within range

Lab values

• Clinically significant disorders of the liver \[cirrhosis, portal hypertension, hepatitis, increased bilirubin (≥1.5 mg/dl), active or uncontrolled cardiovascular disease, symptomatic peripheral vascular disease, (i.e. intermittent claudication), pulmonary diseases (including uncontrolled asthma and restrictive or obstructive lung disease requiring therapy), renal-urinary disorders (calculi, urinary tract obstruction, glomerulonephritis, chronic infection), gastrointestinal disorders (nausea, vomiting, diarrhea or anorexia sufficient to cause weight loss or wasting), or hematocrit levels ≤30 percent in women or ≤35 percent in men.
• Bleeding disorders or requirements for anticoagulation or platelet inhibitors which cannot be safely interrupted since kidney biopsies cannot be performed safely in these individuals.
• INR \> 1.4 (a)
• PTT \> 35 seconds (a)
• Platelet count \< 100,000 uL (a)
• Hemoglobin (Hgb) \< 10 mg/dL (a)

Other

• Massive obesity with body mass index ≥45 kg/m².
  • Kidney biopsies are more technically difficult with massive obesity.
• Known solitary kidney
• Current use of UGT enzyme inducters, lithium, and digoxin
• Blood urea nitrogen (BUN) \> 80 gm/dL

• Aged 18-80 years.
  • The lower age limit was set so renal function test results would not reflect changes associated with growth.
• Diagnosis of type 2 diabetes for ≥ 3 years.
• Estimated GFR \>45 and \< 90 ml/min/1.73m2 as determined from the CKD-EPI equation using serum creatinine (Levey et al., 2009)
• A screening urinary albumin-to-creatinine ratio \<3000 mg/g.
• Willingness to participate after receiving a thorough explanation of the study.
• Participants receiving a RAAS inhibitor must have been receiving the drug at maximum tolerable dose for at least 3 months prior to the study baseline examination.
• Participants receiving a GLP-1 receptor agonist must have been receiving the drug for at least 3 months prior to the study baseline examination.
• Participants must meet the current clinical guidelines for prescribing SGLT2 inhibitors, to maintain FDA-approved standards